Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
David Kuter, MD, DPhil
Advertisement
David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Articles by David Kuter, MD, DPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Sotatercept Indication for PAH
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5
